New challenges in kidney cancer therapy: Sunitinib

Annals of Oncology

Volumn 18, Issue SUPPL. 9, 2007, Pages

  Izzedine, H ^a   Billemont, B ^a   Thibault, F ^a   Rixe, O ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD135 ANTIGEN; CYTOCHROME P450 3A4; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RIFAMPICIN; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DEPIGMENTATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HAIR DISCOLORATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SKIN DISCOLORATION; STOMATITIS; THYROID DISEASE; TREATMENT DURATION; DRUG ANTAGONISM; FORECASTING; KIDNEY TUMOR; PATHOLOGY; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; FORECASTING; HUMANS; INDOLES; KIDNEY NEOPLASMS; PROTEIN-TYROSINE KINASES; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 36049006487     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm298     Document Type: Conference Paper

References (25)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, CA Cancer J Clin 2006; 56: 106-130.
2. Chow WH, Devesa SS, Warren JL et al. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281: 1628-1631.
3. Amato RJ. Renal cell carcinoma: Review of novel single-agent therapeutics and combination regimens. Ann Oncol 2005; 16: 7-15.
4. Negrier S, Perol D, Ravaud A et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of a prospective randomized trial. J Clin Oncol 2005; 23: 380 (Abstract 4511).
5. Heinrich MC, Blanke CD, Druker BJ et al. Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692-1703.
6. Rubin BP, Schuetze SM, Eary JF et al. Molecular targeting of platelet derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002; 20: 3586-3591.
7. Gilliland DG, Griffin JD. Role of FLT3 in leukemia. Curr Opin Hematol 2002; 9: 274-281.
8. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999; 13: 1055-1066.
9. Latif F, Tory K, Gnarra J et al. Identfication of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317-1320.
10. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 2003; 9: 677-684.
11. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of Sul 1248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: Determination of a pharmacokinetic./pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
12. Abrams TJ, Murray LJ, Pesenti E et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003; 2: 1011-1021.
13. Laird AD, Cherrington JM. Small molecule tyrosine kinase inhibitors: Clinical development of anticancer agents. Expert Opin Invest Drugs 2003; 12: 51-64.
14. Baratte S, Sarati S, Frigerio E et al. Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A 2004; 1024: 87-94.
15. Houk BE, Amantea M, Motzer RJ et al. Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006 Am Soc Clin Oncol Annual Meeting Proceedings Part I. Vol. 24, No. 18S.
16. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35.
17. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524.
18. Molzer RJ, Michaelson MID, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
19. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
20. Desai J, Dileo P, Morgan JA et al. Hypothyroidism may accompany SU11248 therapy in a subset of patients (pts) with metastatic (met) gastrointestinal stromal tumors (GIST) and is manageable with replacement therapy. J Clin Oncol 2005 Am Soc Clin Oncol Annual Meeting Proceedings. 23, No. 16S, Part I of II (June 1 Supplement): Abst 3040.
21. Bello C, Houk B, Sherman L et al. Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers. J Clin Oncol 2005 Am Soc Clin Oncol Annual Meeting Proceedings, Vol 23, No. 16S, Part I of II (June 1 Supplement): Abst 3078.
22. Rini B, Rixe O, Bukowski R et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates antitumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol 2005 Am Soc Clin Oncol Annual Meeting Proceedings 23 (suppl): 380s (abstract 4508).
23. Hurwitz H, Savage S, Fernando N et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. J Clin Oncol 2005; Am Soc Clin Oncol Annual Meeting Proceedings. 22: 3012.
24. Rini BI, George DJ, Michaelson MD et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; Am Soc Clin Oncol Annual Meeting Proceedings Part 1. Vol. 24, No. 18S.
25. Zbar B, Tory K, Merino M et al. Hereditary papillary renal cell carcinoma. J Urol 1994; 151: 561-566.